Rockhampton Hospital, Central Queensland Hospital and Health Service, Canning Street, Rockhampton, QLD, 4700, Australia.
The University of Queensland Rural Clinical School, 78 Canning St, The Range, QLD, 4700, Australia.
BMC Anesthesiol. 2021 Feb 16;21(1):53. doi: 10.1186/s12871-021-01275-z.
Midazolam is a benzodiazepine commonly used in procedural sedation and general anaesthesia. Current anaesthetic guidelines advise the avoidance of benzodiazepines in elderly patients due to concerns of an increased risk of delirium. Delirium is associated with significant patient morbidity and mortality, while also increasing health costs. Despite this, midazolam is often used in elderly patients undergoing low risk procedures due to the benefits of rapid onset, anxiolysis and haemodynamic stability compared to other sedatives. To date, studies describing the relationship between midazolam use and delirium in elderly patients undergoing low risk procedures, such as endoscopy, are limited.
This was a prospective observational cohort pilot study identifying the prevalence of delirium pre-procedure and incidence of delirium post-procedure in elderly endoscopy patients receiving midazolam. The study population was elderly patients greater than 65 years of age, without underlying cognitive dysfunction, undergoing elective endoscopy. Electronic databases were used for collection of demographic and clinical information. Delirium was identified through the administration of the Family Confusion Assessment Method survey; this was administered to carers of the study population 24-48 h pre and post procedure to categorically identify the presence or absence of delirium.
Fifty-eight participants were recruited for this study and eighteen were subsequently excluded based upon additional exclusion criteria. Forty patients were included in the final results. American Society of Anaesthesiology Classification (ASA) of patients were as follows: 1 (9 patients), 2 (12 Patients), 3 (16 Patients) and 4 (3 patients). Patients underwent gastroscopy, colonoscopy or combined gastroscopy and colonoscopy. This study identified no cases of delirium in elderly patients after administration of midazolam for elective endoscopy procedures 24-48 h post-procedure. Additionally, a high proportion of elderly patients were found to have received midazolam.
No episodes of delirium were identified in this study. This finding runs counter to current guideline recommendations regarding midazolam use in the elderly patient and that elderly patients undergoing elective endoscopy represent a significantly different patient population compared to those previously studied. This study suggests that in the study population that the risk of delirium in patients exposed to midazolam in elective endoscopy was not demonstrated and that it may be safe to perform experimental studies to elucidate the safety of midazolam in larger studies.
咪达唑仑是一种苯二氮䓬类药物,常用于程序镇静和全身麻醉。目前的麻醉指南建议避免在老年患者中使用苯二氮䓬类药物,因为担心谵妄风险增加。谵妄与患者发病率和死亡率显著相关,同时也增加了医疗保健成本。尽管如此,由于咪达唑仑与其他镇静剂相比具有起效快、抗焦虑和血液动力学稳定的优点,因此在接受低风险手术的老年患者中仍经常使用。迄今为止,描述接受低风险手术(如内镜检查)的老年患者中咪达唑仑使用与谵妄之间关系的研究有限。
这是一项前瞻性观察性队列研究,旨在确定接受咪达唑仑治疗的老年内镜患者术前谵妄的发生率和术后谵妄的发生率。研究人群为年龄大于 65 岁、无潜在认知功能障碍、接受择期内镜检查的老年患者。使用电子数据库收集人口统计学和临床信息。通过实施家庭混乱评估方法调查来识别谵妄;在术前 24-48 小时和术后向研究人群的照顾者进行调查,以明确识别是否存在谵妄。
这项研究共招募了 58 名参与者,其中 18 名随后根据其他排除标准被排除。40 名患者纳入最终结果。患者的美国麻醉医师协会(ASA)分类如下:1 级(9 例)、2 级(12 例)、3 级(16 例)和 4 级(3 例)。患者接受了胃镜检查、结肠镜检查或胃镜和结肠镜联合检查。这项研究在接受咪达唑仑进行择期内镜手术后 24-48 小时,没有发现老年患者出现谵妄。此外,发现大量老年患者接受了咪达唑仑治疗。
本研究未发现谵妄发作。这一发现与当前关于老年患者使用咪达唑仑的指南建议相矛盾,也与之前研究的老年患者不同。本研究表明,在研究人群中,接受择期内镜检查的患者暴露于咪达唑仑的情况下,谵妄风险并未显现,因此可以安全地进行实验研究,以更大规模的研究来阐明咪达唑仑的安全性。